Hashem Haghdoost-Yazdi
7PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|May 13, 2024
Dexmedetomidine, an alpha-2 adrenoceptors agonist, provides a neuroprotective effect for dopaminergic neurons in the substantia nigra and attenuates glucose imbalance in the 6-hydroxydopamine animal model of Parkinson's disease.Seyed Amir Farzam, Shahram Darabi, Hashem Haghdoost-Yazdi
|Feb 14, 2022
Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine-Induced Parkinsonism in Male Rats.Roghaieh Razaghi, Hossein Piri, Hanieh Jafari
|Nov 12, 2021
Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta.Ali Sarbazi-Golezari, Hashem Haghdoost-Yazdi
|Nov 06, 2021
Dopaminergic Neuronal Death in Substantia Nigra Associates with Serum Levels of Total Bilirubin, Selenium, and Zinc: Evidences from 6-Hydroxydopamine Animal Model of Parkinson's Disease.Mohammad Sophiabadi, Nafiseh Rastgoo, Hashem Haghdoost-Yazdi
|Apr 05, 2018
Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model.Mohammad Reza Sarukhani, Hashem Haghdoost-Yazdi, Gilda Khandan-Chelarci
Pageof 2
